Treatment of Heart Failure with Reduced Ejection Fraction: Current Update.
10.3904/kjm.2015.88.2.127
- Author:
Jin Joo PARK
1
;
Dong Ju CHOI
Author Information
1. Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea. djchoi@snu.ac.kr
- Publication Type:Review
- Keywords:
Systolic heart failure;
Practice guideline
- MeSH:
Diagnosis;
Drug Therapy;
Heart Failure*;
Heart Failure, Systolic;
Heart Transplantation;
Hospitalization;
Humans;
Mortality;
Prevalence;
Quality of Life
- From:Korean Journal of Medicine
2015;88(2):127-134
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The prevalence of heart failure (HF) has been steadily increasing and it now creates an enormous social and economic burden. HF is a syndrome characterized by a high mortality rate, frequent hospitalization, a reduced quality of life, and a complex therapeutic regimen. In the last three decades, major progress in both the diagnosis and management of HF has taken place, and the pharmacologic and non-pharmacologic advances have led to a significant improvement in survival and symptoms in HF patients. After an accurate diagnosis, a proper HF management plan requires a multi-level team approach comprised of the correct combination of drug therapy, device therapy, and surgery, including heart transplantation. In this review, we focused on the pharmacologic and non-pharmacologic treatment strategies for HF with reduced ejection fraction. The goal was to develop treatment guidelines based on significant evidence derived from large clinical trials.
